Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.

Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to 6 Dimensions Capital.

The Nikon and Varian-backed cell biology technology developer floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.

The EV battery producer has gone public in China, weeks after raising $193m in a round featuring strategic partner Daimler.

The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.

The ophthalmologic drug developer has gone public three years after being founded by WuXi AppTec-backed 6 Dimensions Capital.

The banking software provider's shares have nearly tripled following an offering in which it floated well above its range.

The Baidu and SoftBank-backed on-demand staff provider floated in the middle of its range in a US offering and its market cap currently stands at about $600m.

The GSK, Amgen and Novo-backed cancer drug developer went public in an upsized offering priced above its range.